Hepatorenal syndrome (HRS)
Epidemiology of hepatorenal syndrome (HRS)
- 10% of patients with cirrhosis and ascites.
Pathogenesis hepatorenal syndrome (HRS)
- Renal vasoconstriction leading to renal failure.
- The renal vasoconstriction is a compensatory effect of RAAS and ADH, triggered by an extreme underfilling in the arterial circulation.
Types of hepatorenal syndrome (HRS)
- Type 1
- Rapidly progressive
- Triggered by an event such as SBP and requiring urgent intervention
- Type 2
- Occurs gradually, as a consequence of aggravation of end-stage liver disease
Treatment of hepatorenal syndrome (HRS)
- Plasma expander, normally human albumin solution
- Terlipressin 0.5-2mg IV four times daily
Click here to download free teaching notes on HRS in the context of decompensated chronic liver disease: Hepatorenal syndrome (HRS)
Perfect revision for medical students, finals, OSCEs and MRCP PACES